Updates from our members.
Achillion Pharmaceuticals is scheduled to present updated clinical data on its ACH-3102 for hepatitis C and its ACH-3422 uridine-analog nucleotide … more
NovaTract Surgical has been issued a patent for the design behind the company’s entry device, the NovaTract™ Laparoscopic Dynamic Retractor … more
Kolltan Pharmaceuticals has announced top-line results from the open-label, dose escalation monotherapy portion of its Phase 1 clinical trial program of KTN3379 in adult patients with advanced solid tumors. KTN3379 is a human monoclonal antibody that blocks the activity of ErbB3, a member of the ErbB family of RTKs … more
Kolltan has filed an S-1 relating to a proposed initial public offering … more
In September Kolltan acquired Xetrios Therapeutics. Through this acquisition, Kolltan has secured exclusive intellectual property (IP) rights focused on human therapeutics targeting the TAM RTK family. TAM RTK targets and related antagonists and agonists provide a potentially new way of harnessing the machinery of immunity to address cancer and other diseases … more